These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20395318)

  • 1. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
    Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC
    J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
    Wardak M; Schiepers C; Cloughesy TF; Dahlbom M; Phelps ME; Huang SC
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1199-209. PubMed ID: 24604590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeatability of
    Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
    J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
    Wardak M; Schiepers C; Dahlbom M; Cloughesy T; Chen W; Satyamurthy N; Czernin J; Phelps ME; Huang SC
    Clin Cancer Res; 2011 Oct; 17(20):6553-62. PubMed ID: 21868765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
    Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
    J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
    Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
    J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluorothymidine kinetics of malignant brain tumors.
    Schiepers C; Chen W; Dahlbom M; Cloughesy T; Hoh CK; Huang SC
    Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1003-11. PubMed ID: 17295039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.
    Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
    J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
    Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
    J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.
    Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J
    Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice.
    Kim SJ; Lee JS; Im KC; Kim SY; Park SA; Lee SJ; Oh SJ; Lee DS; Moon DH
    J Nucl Med; 2008 Dec; 49(12):2057-66. PubMed ID: 18997037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDOPA kinetics in brain tumors.
    Schiepers C; Chen W; Cloughesy T; Dahlbom M; Huang SC
    J Nucl Med; 2007 Oct; 48(10):1651-61. PubMed ID: 17873130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
    Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
    J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
    Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
    J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.
    Frings V; Yaqub M; Hoyng LL; Golla SS; Windhorst AD; Schuit RC; Lammertsma AA; Hoekstra OS; Smit EF; Boellaard R;
    J Nucl Med; 2014 Sep; 55(9):1417-23. PubMed ID: 24970910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.